Skip to main content

Table 3 Event, Maintenance and therapy costs (indexed to £UK 2007)

From: Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

Variable

Cost

Source

Ischaemic Heart Disease, fatal event

£0

UKPDS Study No.65†

Ischaemic Heart Disease, Non-fatal event

£2,388

UKPDS Study No.65†

Ischaemic Heart Disease, Maintenance

£601

UKPDS Study No.65†

Myocardial Infarction, Fatal event

£1,404

UKPDS Study No 65†

Myocardial Infarction, Non-fatal event

£4,961

UKPDS Study No.65†

Myocardial Infarction, Maintenance

£566

UKPDS Study No.65†

Congestive Heart Failure, Fatal event

£0

UKPDS Study No.65†

Congestive Heart Failure, Non fatal event

£2,707

UKPDS Study No.65†

Congestive Heart Failure, Maintenance

£769

UKPDS Study No.65†

Stroke, Fatal event

£4,124

UKPDS Study No.65†

Stroke, Non-fatal event

£2,885

UKPDS Study No.65†

Stroke, Maintenance

£304

UKPDS Study No.65†

Blindness, Event

0

O'Brien et al. [37]

Blindness, Maintenance

£1,013

O'Brien et al. [37]

Dialysis, Event and Maintenance

£20,049

Baboolal et al. [38]

Amputation, Fatal event

£10,311

UKPDS Study No.65†

Amputation, Non-fatal event

£10,311

UKPDS Study No.65†

Amputation, Maintenance

£366

UKPDS Study No.65†

Hypoglycaemia, Event

£93.85

Leese GP et al. [6]; DCCT hypoglycaemia report*

  1. † Data from: Clarke P, Gray A, Legood R, Briggs A, Holman R: The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine 2003, 20:442–450.
  2. * Data from: The DCCT Research Group: Epidemiology of severe hypoglycemia in the diabetes control and complications trial. American Journal of Medicine 1991, 90:450–459.